BACKGROUND Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL). METHODS Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA). RESULTS The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 μg/L vs. 0.24 μg/L, P = 0.003). A further increase in S-TK1 was observed during the treatment. The S-TK1 concentrations were higher in patients with advanced stage disease, low B-Hb, elevated P-LD and in those with B-symptoms. A high ESR correlated with low S-TK1. CONCLUSIONS The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable conclusions difficult.

中文翻译：

---

在霍奇金淋巴瘤患者中使用一种新的基于抗体的测定法测量胸苷激酶 1 的血清浓度。

背景胸苷激酶1（TK1）是一种与DNA合成相关的细胞内蛋白质，在G1期表达并在M期保持升高，具有作为细胞增殖的生物标志物的潜力。在这项研究中，我们探讨了 TK1 在霍奇金淋巴瘤 (HL) 中的可能用途。方法 使用前瞻性收集的生物库血清样本测量 46 名新诊断的 HL 患者的血清 TK1 (S-TK1) 浓度。使用基于抗体的新型 TK1 免疫吸附试验 (ELISA) 分析样品。结果 与健康对照组相比，HL 患者的 S-TK1 浓度升高（中位数 0.32 μg/L 对 0.24 μg/L，P = 0.003）。在治疗期间观察到 S-TK1 的进一步增加。晚期疾病、低 B-Hb 患者的 S-TK1 浓度较高，P-LD 升高和有 B 症状的患者。高 ESR 与低 S-TK1 相关。结论 研究结果表明，使用新的基于抗体的测定法测量的 S-TK1 有可能成为 HL 的生物标志物。然而，虽然与健康对照相比，基线时 S-TK1 水平升高，但患者数量有限且随访时间相对较短，因此难以得出可靠的结论。